Bionano Genomics (BNGO) Gains from Investment Securities (2017 - 2024)

Bionano Genomics has reported Gains from Investment Securities for 6 years, with the latest figure at -$5.8 million in Q3 2024.

• Quarterly Gains from Investment Securities fell 1962.58% year-over-year to -$5.8 million in Q3 2024, while the trailing twelve-month figure through Jun 2025 was -$5.8 million (up 34.36% YoY) and the FY2024 annual result came in at -$10.9 million, down 644.87% from the prior year.
• Gains from Investment Securities fell to -$5.8 million in Q3 2024 per BNGO's latest filing, from -$4.5 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $1.4 million in Q2 2023 and troughed at -$5.8 million in Q3 2024.
• A 4-year average of -$997500.0 and a median of $79000.0 in 2022 frame the typical range for Gains from Investment Securities.
• The widest YoY moves for Gains from Investment Securities: up 1708.86% in 2023, down 5150.63% in 2023.
• Over 4 years, Gains from Investment Securities stood at $66000.0 in 2021, then gained by 19.7% to $79000.0 in 2022, then slumped by 5150.63% to -$4.0 million in 2023, then tumbled by 44.71% to -$5.8 million in 2024.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered -$5.8 million, -$4.5 million, and -$640000.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.